6 February 2024 - Public reimbursement for Vascepa is now available in Ontario, Quebec, British Columbia, Saskatchewan, New Brunswick, Northwest Territories, ...
31 January 2024 - In partnership with Sumitomo, Pfizer is proud to announce that supply of Myfembree (relugolix 40 mg, estradiol ...
16 January 2024 - Fenfluramine costs more than $3,000 a month and is not approved by Health Canada. ...
18 December 2023 - Helping make Canada's drug system more sustainable and better prepared for the future. ...
27 November 2023 - Of the 2556 prescription drugs marketed by 89 companies in the study period, 256 (10.0%) had a ...
10 November 2023 - It’s been one year since CADTH launched the Post-Market Drug Evaluation (PMDE) Program to provide decision-makers with ...
7 November 2023 - Mitsubishi Tanabe Pharma Canada today announced that Radicava oral suspension (edaravone) is now covered under the Prince ...
2 November 2023 - Recommendation based on demonstrated clinical benefit in Phase 3 trial. ...
27 October 2023 - Latuda is a drug to treat schizophrenia. It costs about $4,000 per month in the US. ...
12 October 2023 - Today, the Honourable Mark Holland, Minister of Health, announced a new appointment to the Patented Medicine Prices ...
20 September 2023 - A recent report by the Patented Medicine Prices Review Board shows increased growth for private drug ...
12 September 2023 - Paladin Labs announced today that CADTH has recommended that Xcopri (cenobamate) be publicly reimbursed as adjunctive therapy ...
29 August 2023 - Mitsubishi Tanabe Pharma Canada today announced that Radicava oral suspension (edaravone) is now covered under the New ...
18 August 2023 - CADTH is establishing an industry task force that will build upon the recently released guidance for reporting ...
22 August 2023 - The Patented Medicine Prices Review Board published today the 7th edition of its annual Meds Entry Watch ...